ZyVersa Therapeutics, Inc. (ZVSA)
After hours:
| Previous close | 4.8600 |
| Open | 4.9000 |
| Bid | 4.3900 x 100 |
| Ask | 4.6100 x 100 |
| Day's range | 4.4467 - 5.0765 |
| 52-week range | 4.4400 - 180.2500 |
| Volume | |
| Avg. volume | 419,726 |
| Market cap | 3.408M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1,089.7000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.00 |
GlobeNewswireZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR 200 in patients with diabetic kidney disease planned to begin H1-2024.GLP toxicology studies for Inflammasome ASC Inhibitor IC 100 scheduled to begin H1-2024, with planned Investigational New Drug (IND) submission Q4-2024, and Phase 1 clinical trial initiation Q1-2025.Atherosclerosis preclinical data readout for Inflammasome ASC Inhibitor IC 100 on schedule for
- GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of numerous inflammatory diseases.Mr. Glover welcomes one-on-one meetings to discuss ZyVersa’s technology, pipeline assets, and key development milestones. WESTON, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “Zy
- GlobeNewswire
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates that multiple inflammasome triggers (NLRP1 and pyrin) govern the inflammatory response in Alzheimer’s Disease (AD), and that release of inflammasome laden extracellular vesicles (EV) into the blood induce significant inflammation in cardiovascular cells.ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to inhibit multiple types of
